Page last updated: 2024-08-21

cyclopentane and mk 2206

cyclopentane has been researched along with mk 2206 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bi, Y; Chen, X; Cui, D; Shu, J; Xiong, X; Zhao, Y	1

Other Studies

1 other study(ies) available for cyclopentane and mk 2206

Article	Year
AKT inhibitor MK-2206 sensitizes breast cancer cells to MLN4924, a first-in-class NEDD8-activating enzyme (NAE) inhibitor. Cell cycle (Georgetown, Tex.), 2018, Volume: 17, Issue:16 Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclopentanes; Female; Heterocyclic Compounds, 3-Ring; Humans; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Signal Transduction; Ubiquitin-Activating Enzymes	2018

Article

Year

AKT inhibitor MK-2206 sensitizes breast cancer cells to MLN4924, a first-in-class NEDD8-activating enzyme (NAE) inhibitor.

Cell cycle (Georgetown, Tex.), 2018, Volume: 17, Issue:16

Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclopentanes; Female; Heterocyclic Compounds, 3-Ring; Humans; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Signal Transduction; Ubiquitin-Activating Enzymes

2018